FGF23
Fibroblast growth factor 23
As of the edition of 20 October 2026, FGF23 (fibroblast growth factor 23, UniProt Q9GZV9) has 1 drug tested at it and 1 company on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9GZV9
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 6
- Disease areas
- Inherited and neonatal; Bones, joints and muscles; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Cancer; Nervous system; Hormones
- Registered trials of its drugs
- 28
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Burosumab | Marketed | Phase 4 | Ends 2030 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Kyowa Kirin | Route B |
The other 0 companies at FGF23
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at FGF23, ranked, with the facts behind eachRequest access. Nothing is shown until you do.